On May 12, 2026, a coalition of clinical, academic, and patient organizations officially renamed polycystic ovary syndrome — known for decades as PCOS — to polyendocrine metabolic ovarian syndrome, or PMOS.
It may seem that changing the letters is not a big deal. However, the shift from PCOS to PMOS corrects a misrepresentation that has contributed to diagnostic delays, fragmented care, and stigma for a condition millions of women worldwide experience.
What Was Wrong With “PCOS”
The term polycystic ovary syndrome was based on the appearance of multiple follicles on ovarian ultrasound. The name has stuck since 1930.
The “cysts” in the old name are not actually cysts. They are immature egg sacs that fail to ovulate properly. For decades, women have been told they had “cysts on their ovaries,” causing confusion, fear, and in some cases missed diagnoses when no cysts appeared on imaging.
Due to the name, this has also led the belief that PCOS was primarily a gynecological issue, with the ovaries at the center of the syndrome. However, insulin resistance, testosterone excess, and disrupted endocrine signaling are part of the diagnosis, which are all far beyond reproductive anatomy. These are parts of how metabolism works, not just reproduction. This has led to the treatment of the syndrome missing the endocrine part of the condition and the treatment options being unclear if they are to fall under gynecology or endocrinology. This leads to misdiagnosis and unclear treatment for many women.
Why PMOS – Polyendocrine Metabolic Ovarian Syndrome – Is a Better Description
The new name was very deliberately chosen.
Polyendocrine recognizes that the condition involves multiple hormonal disturbances — insulin dysregulation, testosterone excess, and disrupted hypothalamus signaling — placing it accurately within endocrinology rather than reproductive medicine alone.
Metabolic is the most clinically significant addition. Women with this diagnosis have a higher risk of developing type 2 diabetes, cardiovascular disease, and metabolic syndrome, which are all primary features. Without a focus on metabolism, many women do not get the appropriate metabolic treatment.
Ovarian is retained because irregular ovulation and disrupted follicle development remain an important part of many women’s experiences. The name does not erase the reproductive part, however it does not place sole focus on it.
Why the Change Matters
The new language matters. This updated description of the diagnosis places more emphasis on the effect of overall metabolism. This makes it easier for clinicians to recognize the full encompassing influence on overall health for women.
The renaming does not change diagnostic criteria or treatment protocols. Women previously diagnosed with PCOS retain their diagnosis under the new name. However, over time the recognition of PMOS as a systemic metabolic and hormonal disorder will allow for more research and more accurate treatment protocols to aid with balancing the syndrome.
This can be seen as one giant leap for womankind.
